Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Right to Try

U.S. Senate’s ‘Right to Try’ Bill Could Face Slower Action in House

Washington, DC, August 15, 2017Roll Call reports that a U.S. Senate-passed “right to try” bill that is intended to help dying patients access experimental drugs, which have yet to receive Food and Drug Administration (FDA), likely will face lengthier deliberations in the U.S. House of Representatives.

While the Senate fast-tracked the bill on August 3, the House will likely subject it to a hearing and markup before bringing it up to a vote, according to congressional aides and a lobbyist.

The bill would reduce some of the paperwork involved in getting access to experimental treatments, and would offer protections to the drug companies who choose to make drugs available outside of a clinical trial. Continue reading

U.S. Senate Passes ‘Right to Try’ Bill to Help Terminally Ill Patients Access Experimental Drugs

Washington, DC, August 3, 2017 — Laurie McGinley reports in The Washington Post that the United States Senate today passed by unanimous consent a measure designed to make it easier for terminally ill patients to get access to experimental treatments without oversight from the Food and Drug Administration.

The “right-to-try” legislation has been championed by the libertarian Goldwater Institute, which has worked to pass similar legislation in 37 states.

The federal version, now headed to the House, would bar the government from blocking patients from getting access to medications that have undergone only preliminary testing in humans. Continue reading